|
|
Alhydroxiquim-II |
|
Vaxjo ID |
113 |
|
Vaccine Adjuvant Name |
Alhydroxiquim-II |
|
Alternative Names |
Algel-IMDQ |
|
Adjuvant VO ID |
VO_0005301
|
|
Description |
small molecule with TLR7/TLR8 receptor; activates an agonistic TLR7/TLR8 response in lymph nodes when small molecule detaches from alum; causes Th1 immune system response |
|
Stage of Development |
Licensed |
|
Location Licensed |
COVAXIN licensed in India uses this adjuvant |
|
Host Species for Testing |
|
|
Components |
chemisorbed imidazoquinoline into aluminum hydroxide gel |
|
Storage |
ambient or 4C |
|
Preparation |
chemisorbtion of imidazoquinoline into aluminum hydroxide gel |
|
Function |
Type: combination vaccine adjuvant. Target Receptor: Toll-like receptor 7 (TLR7) | Toll-like receptor 8 (TLR8). Induces Th1-biased immune profile. TLR7/8 dual agonist - lymph node delivery |
|
Safety |
It is a stable adjuvant. It appears overall safe since it has been used in the licensed COVAXIN vaccine against COVID-19. |
| Related Vaccine(s) |
|
| References |
Ella et al., 2021: Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, Panda S, Gupta N, Reddy P, Verma S, Kumar Rai S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Rao V, Guleria R, Ella K, Bhargava B. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. The Lancet. Infectious diseases. 2021; 21(5); 637-646. [PubMed: 33485468].
VAC #12: [https://vac.niaid.nih.gov/view?id=12]
|
|
